Comparison of Insulins Aspart and Lispro in Insulin Pumps

Type 1 Diabetes Mellitus Clinical Trial

Official title:

A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00461331
• Other study ID #: F-0215
• Status: Completed
• Phase: Phase 4
• Start date: October 2004
• Est. completion date: August 2008

Study information

• Verified date: January 2021
• Source: Tulane University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare the glycemic control between insulins aspart and lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes using an insulin pump.

Description:

Continuous subcutaneous insulin infusion (Insulin pump therapy) is a well established tool for the management of type 1 diabetes. In clinical trials, insulin pump therapy has been shown to have increased efficacy over multiple daily injections. However, the overall glycemic control in patients using insulin pumps has been disappointing. The recommended duration of "needle use" in insulin pump treatment is 48 hours, based on anecdotal observations.

One of the reasons for the suboptimal control may be that patients do not adhere to the advice of changing their pump infusion line every 48 hours. However, it is possible that the loss of glycemic control may be related to instability of insulin in the pump/line. In addition to premeal loss of control after 48 hours of line change, very little is known about post-prandial hyperglycemia leading to loss of efficacy of the insulin via an insulin pump bolus. The development of continuous glucose monitoring system (CGMS) and new tests for short term fluctuations in glucose control such as 1,5-anhydroglucitol make it easier to evaluate the impact of short term loss of control in patients using the insulin pump who delay changing their lines.

The different variables will be compared between the two insulins using a paired t test.

1. Glycemic control will be will be compared 24 to 100 hours after pump infusion line change using CGMS and daily serum 1,5-anhydroglucitol.

2. Post prandial glycemic excursions in plasma glucose following a standardized breakfast 48, 72, and 96 hours after a pump infusion line change will be compared.

3. The used pump infusion line will be collected from the patient and analyzed for insulin binding to the plastic, as well as other possible effects that may determine its role in loss of glycemic control.

4. Comparison of some of the markers of coagulation, inflammation, protein glycation and oxidative stress 48, 72, and 96 hours after a pump infusion line change.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2008
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Type 1 Diabetes treated with a pump for at least 3 months

Exclusion Criteria:

• Pregnancy

• Plasma Creatinine > 1.2 mg/dl

• Inability to give informed consent

• HbA1c > 8%

• Known or suspected hypersensitivity to trial drugs or any of their components

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Insulin Aspart
Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
• Insulin Lispro
Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.

Locations

Country	Name	City	State
United States	Clinical Translational Unit - Tulane School of Medicine	New Orleans	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Tulane University Health Sciences Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change	For each test period, we measured the duration of time that the same pump infusion line could be kept in place without losing glycemic control. Loss of glycemic control was defined as capillary blood glucose level >300 mg/dL.	24 to 100 hours after last pump infusion line change
Secondary	Daily Serum Glycomark Levels 48 to 100 Hours After Keeping the Same Pump Infusion Line in Place	Daily serum glycomark levels between day 3 and day 5 after the pump infusion line change. These levels were measured for both the test periods.	48 to 100 hours after keeping the same pump infusion line in place
Secondary	Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place	Free 15-F2t isoprostane was measured between days 3 and 5 after the keeping the same pump infusion line in place. It is a marker of oxidative stress due to hyperglycemia that was being compared between the two test periods.	Between 48, 72 and 96 hours after the last pump infusion line change